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Available online 4 June 2013Abstract Fibronectin is a major extracellular matrix glycoprotein with several alternatively spliced variants, including extra
domain A (EDA), which was demonstrated to promote tumorigenesis via stimulating angiogenesis and lymphangiogenesis. Given that
CD133+/CD44+ cancer cells are critical in tumorigenesis of colorectal cancer (CRC), we hypothesize that fibronectin EDAmay promote
tumorigenesis by sustaining the properties of CD133+/CD44+ colon cancer cells. We found that tumor tissue and serum EDA levels are
substantially higher in advanced versus early stage human CRC. Additionally we showed that tumor tissue EDA levels are positively
correlated with differentiation status and chemoresistance, and correlated with a poor prognosis of CRC patients. We also showed
that in colon cancer cells SW480, CD133+/CD44+ versus CD133−/CD44− cells express significantly elevated EDA receptor integrin
α9β1. Silencing EDA in SW480 cells reduces spheroid formation and cells positive for CD133 or CD44, which is associated with reduced
expressions of embryonic stem cell markers and increased expressions of differentiation markers. Blocking integrin α9β1 function
strongly reversed the effect of EDA overexpression. We also provided evidence suggesting that EDA sustains Wnt/β-catenin signaling
activity via activating integrin/FAK/ERK pathway. In xenograft models, EDA-silenced SW480 cells exhibit reduced tumorigenic and
metastatic capacity. In conclusion, EDA is essential for the maintenance of the properties of CD133+/CD44+ colon cancer cells.
© 2013 Elsevier B.V. All rights reserved.Introduction
New cases for colorectal cancer (CRC) are about 1 million
per year worldwide in 2002 (Parkin et al., 2005). In the
United States, the number is estimated to reach 1.5 million
in 2009 and the CRC is the second leading cause of cancer⁎ Corresponding author. Fax: +1 301 405 0223.
⁎⁎ Corresponding author. Fax: +86 23 65425219.
E-mail addresses: LYU123@umd.edu (L. Yu),
lianghoujie@sina.com (H. Liang).
1873-5061/$ - see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.scr.2013.05.009death (Jemal et al., 2009). A growing body of evidence
suggests that some subpopulations of cancer cells within a
tumor are capable of self-renewing, differentiating into a
phenotypically heterogeneous progeny, and surviving harsh
microenvironment (Al-Hajj et al., 2003; Bonnet and Dick,
1997; Lapidot et al., 1994; Singh et al., 2003). These subset
of tumor cells, though aberrant, are operationally referred
to as tumor progenitor cells (Chaffer and Weinberg, 2011;
Clarke et al., 2006; Gupta et al., 2009; Reya et al., 2001).
Within certain tumors as many as 25% of the cancer cells
have been suggested to possess the properties of tumor
progenitor cells (Kelly et al., 2007; Quintana et al., 2008).
821EDA-integrin α9β1 sustains CD133+/44+ colorectal cancer cellThe existence of tumor progenitor cells in a tumor suggests
that efficient cancer therapy may require simultaneous
targeting of both the bulk of non-progenitor cells as well
progenitor cells (Chaffer and Weinberg, 2011).
Using cell surface markers coupled with fluorescence-
activated cell sorting (FACS), several groups have isolated
from human CRC specimens several subpopulations of cancer
cells that have the properties of tumor progenitor cells,
including CD133 positive (CD133+) subpopulation (O'Brien et
al., 2007; Ricci-Vitiani et al., 2007), cells positive for both CD44
and epithelial cell adhesion molecule (epCAM) (epCAMhigh/
CD44+) (Dalerba et al., 2007), and CD26+ cells (Pang et al.,
2010). In cultured human CRC cell lines HT29 and SW1222,
CD44 and CD24 double positive cells have been reported to
have tumor progenitor cell properties, and intriguingly, a
single CD44+/CD24+ cell from SW1222 cell line, when grown in
matrigel, is capable of forming large megacolonies that
differentiate into enterocyte, enteroendocrine, and goblet
cell lineages (Yeung et al., 2010). Clinicopathological studies
have suggested that CD133 is an independent prognostic
marker for low survival in CRC patients (Choi et al., 2009;
Horst et al., 2009; Li et al., 2009a; Wang et al., 2009). Taken
together, the aforementioned findings imply that targeting
CD133+ and CD44+ cancer cells or pathways sustaining CD133+/
CD44+ subpopulation might be an efficient strategy for CRC
therapy.
Tumor microenvironment plays critical roles in regulating
tumor evolution, growth and metastasis (Allen and Louise
Jones, 2010; Kenny et al., 2007). Cancer cells interact with
their extracellular matrix (ECM) during proliferation and
migration. Fibronectin is an important ECM glycoprotein with
several alternatively spliced variants (ffrench-Constant, 1995).
We and others have shown that the alternative extra domain A
(EDA) of fibronectin promotes angiogenesis, lymphangiogenesis
andmetastasis of colorectal tumors (Ou et al., 2011, 2010; Rybak
et al., 2007). The expression levels of EDA are linked tomigration
capacity of primary glioma cells (Ohnishi et al., 1998). EDA
modulates cell behaviors via binding to its cell surface integrin
receptors consisting of α and β subunits (Cabodi et al., 2010; Cox
et al., 2010; Desgrosellier and Cheresh, 2010; Hynes, 2002).
Recently, integrins were used for selection of human neural
progenitor cells (Hall et al., 2006) and for enrichment of tumor
progenitor cells in glioblastoma (Lathia et al., 2010), breast
cancer (Allen et al., 2011; Vaillant et al., 2008), and prostate
cancer (Patrawala et al., 2007). Integrin a9β1 is a receptor for
fibronectin EDA (Shinde et al., 2008), and it was recently
implicated in promotion of tumor cell invasion in breast cancer
(Allen et al., 2011).
Collectively, these previous studies led us to the hypothesis
that EDA may act as a pivotal factor for maintaining the
properties of CD133+/CD44+ subpopulation in CRCs. In this
study, we tested this hypothesis and found that EDA levels are
substantially higher in tumor tissues and serum of advanced
versus early stage CRC patients, and correlated with a poor
prognosis of CRC patients. We demonstrated that EDA expres-
sion is required for maintaining CD133+ and CD44+ subpopula-
tions and tumor colony forming capacity in SW480 human CRC
cells. In vivo, we found that inhibiting EDA expression in SW480
cells reduces their growth and metastasis. Additionally we
provided evidence suggesting that the focal adhesion kinase
(FAK)/ERK/β-catenin signaling pathway is involved in EDA
function. Our finding for the first time links EDA to CD133+/CD44+ subpopulation properties and Wnt/β-catenin activity of
colorectal cancer cells.
Materials and methods
Tissue and blood samples
A tissue chip consisting of 105 human CRC specimens and 10
human normal colorectal tissues for statistical analysis of
clinicopathological features was purchased from Xian-Yi-Lina
Biological Technology (China). According to the information
from the tissue chip company, the ten normal human colon
tissues were obtained from tissue biopsies of non-cancer
subjects who had undergone colonoscopy examination. A tissue
chip consisting of 56 human CRC biopsy specimens collected at
our hospital was used for analysis of chemotherapy resistance
parameters. Another tissue chip consisting of 86 human CRC
biopsy specimens collected at our hospital was used for analysis
of the correlation between EDA expression levels and disease
free survival (DFS) of CRC patients. A set of chips consisting of
176 human CRC specimens with overall survival follow-up
information were purchased from Shanghai Outdo Biotech
(China) and used specifically for the analysis of the correlation
between EDA expression levels and overall survival (OS) of CRC
patients. A separate set of 40 human CRC tissue specimens for
immunofluorescence microscopy studies and 77 blood samples
used for measuring blood EDA concentrations were collected
from CRC patients who had undergone surgeries or biopsy at
our hospital. Tumors were staged by anatomic pathologists in
the Department of Pathology of our hospital, according to the
Union for International Cancer Control classification system. All
experiments were approved by the ethics committee of
Southwest Hospital, the Third Military Medical University.
Cell culture
The human SW480 CRC cell line was obtained from the
American Type Culture Collection (Manassas, VA), and
maintained in Leibovitz's L-15 Medium
(Invitrogen Corp.) supplemented with 10% fetal bovine
serum at 37 °C under 5% CO2.
Antibodies
A monoclonal anti-focal adhesion kinase (FAK) (Catalog#:
20431) antibody was obtained from Upstate Biotechnology
(Upstate, Waltham, MA). A polyclonal anti-phospho-FAK
(phospho-Tyr397) (Catalog#: KAP-TK131D) antibody and a
CD44/-PE conjugated antibody (Catalog#: 561858, Isotype
IgG2b, κ) were from BD Biosciences (San Diego, CA). A
CD133/-APC conjugated antibody (Catalog#: 130-090-854)
was obtained from Miltenyi Biotech. A rabbit monoclonal
anti-phospho-Akt (Catalog#: 4058L), a rabbit polyclonal anti-
Akt antibody (Catalog#: 9272S), a rabbit monoclonal anti-
Phospho-p44/42 MAPK (Erk1/2) (Catalog#: 4370) and a mouse
monoclonal anti-Erk antibody (Catalog# 4696S) were from Cell
Signaling (Beverly, MA). Mouse monoclonal antibodies against
human fibronectin EDA domain (IST-9) (Catalog#: ab6328) and
integrin α9β1 (Y9A2) (Catalog#: ab27947), an isotype control
antibody (mouse IgG1) for integrin α9β1, a rabbit monoclonal
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anti-CD133 antibody (Catalog#: ab27699) and a goat polyclon-
al anti-OCT4 antibody (Catalog#: ab27985) were purchased
from Abcam Inc. A goat polyclonal antibody raised against
cleaved caspase-3 (h176) (Catalog# sc-22171), a goat poly-
clonal antibody against cleaved caspase-9 (h331) (Catalog#:
sc-22182), a rabbit polyclonal antibody against cleaved poly
ADP-ribose polymerase (PARP) (h215)-R (Catalog#: sc-23461-
R) and a cyclin D1 (H-295) (Catalog#: sc-753), and a mouse
monoclonal antibody against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (D-6) (Catalog#: sc-166545), were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A
mouse monoclonal antibody against active β-catenin (Cata-
log#: 05-665), a rabbit polyclonal antibody against anti-β-
catenin (Catalog#: AB19022) and a rabbit polyclonal anti-
Glut1 antibody (Catalog#: 07-1401) were from Millipore Corp.
ELISA
EDA concentrations in the sera of patients with CRC were
quantified using a human fibronectin EDA-specific ELISA Kit
(BPE301106H, RB, Shanghai Hushang Biotechnology Co., Ltd.).
Immunohistochemical and immunofluorescence
microscopy studies
All tissue chip slides were routinely dewaxed, rehydrated,
and prepared for immunohistochemistry. The slides were
incubated in 0.3% H2O2 in methanol for 30 min to block
endogenous peroxidase. Antigens were retrieved with
10 mmol/l sodium citrate (pH 6) for 15 min in a microwave
oven. The slides were then incubated with the selected
antibody at 37 °C for 1 h and at 4 °C overnight. Slides without
treatment with the primary antibody served as negative
controls. The slideswere developedwith an EnVisionTMmethod
(DAKO, Capinteria, CA). The slides were visualized using the
diaminobenzidine solution (DAKO, Capinteria, CA), and then
lightly counterstained with hematoxylin. Evaluation of immu-
nohistochemical staining reaction was performed in accordance
with the Immunoreactive Score (IRS). IRS = SI (staining intensi-
ty) X PP (percentage of positive cells). Negative SI = 0; Weak
SI = 1; Moderate SI = 2; Strong SI = 3. Negative PP = 0; 10%
PP = 1; 11–50% PP = 2; 51–80% PP = 3; and N80% PP = 4. Ten
microscopic fields (100×) from different areas of each tissue
section on a tissue chip were used for the IRS evaluation. Slides
were examined and scored independently by 3 pathologists
blinded to the patient information.
Frozen tissue samples for immunofluorescence staining
were cut into 4 μm serial sections. All the frozen sections were
fixed in ice-acetone for 20 min, washed with PBS for 3 times
for 5 min each, and incubated for 30 min at room temperature
in a protein-blocking solution. The sections were incubated
with the primary antibodies for 1 h at 37 °C and then at 4 °C
overnight. After wash, the sections were incubated at 37 °C
for 1 h with appropriate secondary antibodies, including FITC-
conjugated goat anti-rabbit IgG (1:50, Santa Cruz), FITC-
conjugated goat anti-mouse IgG, (1:50, Santa Cruz), or TRITC-
conjugated goat anti-mouse IgG, (1:50, Beyotime, China). The
sections were counterstained with Hoechst 33258 to reveal
cell nuclei. The specificity of a primary antibody was verified
by omitting that antibody in the reaction.FAK and control shRNA plasmids and establishment
of stable cell lines
One pair of oligonucleotides with a short hairpin was designed
based on the human FAK cDNA sequences (GenBank accession
no. L13616) to target human FAK (forward: 5′-GATCCCCCCACCT
GGGCCAGTATTATTTCAAGAGAATAATACTGGCCCAGGTGGTTTT
TGGAAA-3′ and reverse: 3′-GGGGGTGGACCCGGTCATAAT
AAAGTTCTCTTATTATGACCGGGTCCACCAAAAACCTTTTCGA-5′).
A pair of control primers was also synthesized to generate a
control shRNA construct (forward: 5′-GATCCCCGA CGTGGG
ACTGAAGGGGTTTCAAGAGAACCCCTTCAGTCCCACGTCTTTTTG
GAAA-3′ and reverse: 3′-GGGCTGCA CCCTGACTTCCCCAAA
GTTCTCTTGGGGAAGTCAGGGTGCAGAAAAACCTTTTCGA-5′),
which had no homology to relevant human genes. These
shRNAs were then inserted into pGenesil-l vector. All
resultant constructs were verified by DNA sequencing, and
then transfected into SW480-derived CD133+/CD44+ cells
stably overexpressing EDA with lipofectamineTM 2000
transfection reagent (Invitrogen, Carlsbad, CA, USA).
Transfected cells were enriched by selection for 1 week with
1 mg/ml G418. Three stable cell lines were established,
including an untransfected group, a line expressing a control
shRNA, and a cell line expressing FAK shRNA.
Flow cytometry analysis of cell cycle distribution
Cells were trypsinized and washed with PBS for 3 times. The
cells were resuspended in 0.5 ml PBS, fixed for 24 h in 75%
alcohol, and then resuspended in PBS containing 50 μg/ml
of propridium iodode (PI) and 10 μg/ml of RNasaA, The cells
were incubated at room temperature for 20 min in the dark
prior to flow cytometry analysis using FCM (FACSCan,
Becton Dickinson, San Jose, CA). The program used for the
analysis was ModFit Version 5.2 from Verity Software House
(Topsham, ME).
Protein extraction and Western blotting
Cell lysates were prepared with M-PER Mammalian Protein
Extraction Reagent (PIERCE, PA, USA). A total of 30 μg of
lysate proteins were separated by SDS-PAGE after heat
denature, transferred onto PVDF membranes, and incubated
with 5% non-fat milk dissolved in PBS-Tween 20 solution for
1 h, followed by incubation with a primary antibody overnight
at 4 °C. After wash, the membranes were incubated with an
appropriate HRP-conjugated secondary antibody, and then
developed with enhanced chemiluminescence (ECL) detection
reagents (Amersham Pharmacia Biosciences).
Co-immunoprecipitation assay
Total protein lysates (500 μg) from each sample were
immunoprecipitated in 400 μl lysate buffer containing 2 μl
anti-EDA mouse monoclonal antibody and inhibitors of
various proteases, phosphotases and kinases at 4 °C for
4 h with rotation. Protein A-conjugated agarose beads
(25 μl) were then added into the immunoprecipitation
reaction with an additional 5 h of rotation at 4 °C. The
antigen-antibody complexes were precipitated by a quick
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Controls included an aliquot of rabbit serum to replace the
EDA antibody, in the immunoprecipitation reaction. The
pellets were suspended in 20 μl of 2× SDS reducing Western
blot loading buffer and boiled for 10 min, followed by
SDS-PAGE. The EDA-immunoprecipitates were subjected to
Western blot assay to detect EDA and integrin α9β1 in the
immunoprecipitates.
Lentiviral particles and establishment of stable
cell lines
The lentiviral particles were purchased from GeneChem Co.,
Ltd. (Shanghai). Stably transfected cells were established
following the manufacturer's instructions.
Isolation of CD133+/CD44+ subpopulation from
SW480 cells
SW480 cells were cultured in serum free Leibovitz's L-15
Medium with bFGF (10 ng/ml), and EGF (10 ng/ml) (stem cell
culture medium) for at least 24 h to enhance expression of
surface antigens. Cells were then labeled with CD133/-APC
conjugated antibody and a CD44/-PE conjugated antibody and
sorted by fluorescence-activated cell sorting (FACS).
Sphere formation of tumor cells
SW480 cells were cultured overnight. After trypsinization,
the cells were plated in 96-well plates and cultured in the
stem cell culture medium described above. The medium was
refreshed every 3 days to sustain the tumor cell sphere
formation. One week later, the spheres were photographed
and the size and number of spheres were analyzed by ImageJ
(NIH).
Cell apoptosis
Cell apoptosis was measured using the Annexin V-PE
Apoptosis Detection Kit I (BD PharMingen, San Diego, CA,
USA) via the manufacturer's instructions. Briefly, cells were
harvested with mild trypsinization and resuspended in
binding buffer. Samples were stained with Annexin V-PE
and 7AAD. Fluorescence was measured using an 11-color LSR
II (BD Biosciences). Ten thousand events were collected per
sample. Data were analyzed using FlowJo software (Tree
Star, Ashland, OR, USA). Gates were set based on
single-stain controls. Percentage death was measured as
cells that stained positive for either or both 7AAD and
Annexin V.
Clonogenic assay
For clonogenic assays, EDA-overexpressing CD133+/CD44+
cells were plated into 24-well plates and cultured overnight.
The cells were then grown in the same medium containing
the integrin α9β1 antibody (20 μg/l), IST (20 μg/l) or an
isotype IgG (20 μg/l). Ten days later after plating, colonies
were stained using the crystal violet solution and the numberand area of colonies of N50 cells were calculated using
ImageJ software.
In vivo tumor models
Four-to-six week-old Balb/c nude mice (body weight: 16 to
20 g) were purchased from the Experimental Animal Center,
Institute of Laboratory Animal Sciences (China). The mice
were subcutaneously injected with control or EDA silenced
SW480 cells (1 × 106 cells per mouse) at the both thighs. The
mice were sacrificed 6 weeks after injection and the
xenografts were collected.
Metastases were induced by tail vein injection of 1 × 106
control or EDA silenced SW480 cells. Animals were sacrificed
8 weeks after injection. All of our animal studies have been
approved by the Institutional Animal Care and Use Commit-
tee of the Third Military Medical University.
Statistical analysis
Data are expressed as mean ± SEM (standard error of the
mean). The pathologic scoring data of human specimens
were analyzed by 2 biostatisticians in the Department of
Statistics, The Third Military Medical University, China. The
statistical analysis was performed by one-way ANOVA (when
N3 groups) or Students t-test (between two groups) using
Graph Pad Prism software. For cancer survival analysis,
Kaplan–Meier Survival Curves of Overall Survival were used.
For the analysis of correlation between EDA expression
levels and clinical parameters, Fisher's exact test was used.
Differences between the values were considered statistically
significant when P b 0.05.
Results
Fibronectin EDA levels are increased in the tumor
tissues and blood samples of patients with
advanced CRCs
It has been reported that EDA expression levels are
significantly higher in malignant tumors than benign tumors
and normal tissues (Rybak et al., 2007). We have previously
shown that EDA stimulates lymphangiogesis and lymphatic
metastasis of CRC cells (Ou et al., 2010). Based on these
observations, we speculated that EDA levels may be higher
in advanced CRC as well as correlated to clinicopathological
features. To examine this speculation, we used tissue chips
to perform immunohistochemistry staining for the correla-
tion analysis between EDA and clinicopathological features.
Consistently, EDA levels were substantially higher in CRC in
comparison to that in normal colon tissue and were
significantly higher in CRC of clinically advanced stages (III
and IV) relative to early stages (I and II) (Fig. 1a).
Additionally, we assayed EDA concentrations in blood
samples of 77 patients with CRC, and found that EDA
concentrations were significantly increased in patients with
advanced CRC than those with early stage CRC (Fig. 1b). As
shown in Table 1, EDA levels were also correlated with poor
differentiation and metastasis of CRC. To identify the
relationship between tumor tissue EDA levels and patients'
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chemistry with another tissue chip from tumor biopsies of 56
stage III/IV CRC patients without surgery. We found that
tumor tissue EDA levels were negatively correlated with the
Objective Response Rate, an indicator of chemosensitivity
(Table 2). More impressively, the patients with higher EDA
expression levels had poorer disease free survival (DFS)
(Fig. 1c) and overall survival (OS) than those with lower EDA
expression (Fig. 1d). These findings indicate that CGI-58
deficiency promotes CRC progression.
Increased expression of EDA receptor integrinα9β1
in CD133+/CD44+ cancer cells
It has been shown that CD44+ and CD133+ cells play an
important role in tumor initiation and progression (Chaffer
and Weinberg, 2011). Given the increased expression of EDA
in advanced carcinomas (Fig. 1), we hypothesized that EDA
pathway may sustain the CD133+/CD44+ cell subpopulation.
To test this hypothesis, we first examined the levels of EDA,
EDA receptor integrin α9β1, an embryonic stem cell marker
OCT3/4 (Nichols et al., 1998; Takahashi et al., 2007) and a
progenitor cell marker CD133 (Miraglia et al., 1997; Singh et
al., 2004) in human CRC surgical specimens by immunoflu-
orescence microscopy.
We collected 40 tissue specimens consisting of 17
advanced staged CRC (III & IV) and 23 early staged CRC (I &
II). As expected, OCT3/4-positive cells were frequently seenFigure 1 EDA levels in tumor tissues and blood samples are
(a) Immunohistochemistry of the tissue chip containing human CRC s
plasma EDA concentrations in CRC patients with different stages. n
≥60 years old = 16). n = 45 for stages III/IV (male = 25, female = 20; b
analysis of the correlation between EDA expression levels and the Disease
P b 0.01 (Kaplan–Meier Survival Curves; IRS ≤ 6 included in EDA low; IR
between EDA expression levels and the Overall Survival of CRC patient
Survival Curves; IRS ≤ 6 included in EDA low; IRS N 6 included in EDA hiin the EDA-enriched region (Figs. 2a–b). Integrin α9β1 also
colocalized with CD133 (Figs. 2a–b).
To determine if integrin α9β1 expression levels differ
between CD133+/CD44+ and CD133-/CD44− cells, we sepa-
rated these two subsets of cells in cultured SW480 human
CRC cells by the fluorescence-activated cell sorter, and
measured integrin α9β1 mRNA as well as protein levels
respectively. Interestingly, the EDA receptor integrin α9β1
mRNA levels were N2.5-fold higher in cells positive for
CD133 and CD44 than those negative for these two cell
surface markers (Fig. 2c). Consistently, the integrin α9β1
protein was more abundant in CD133+/CD44+ cells than
CD133−/CD44− cells (Fig. 2d). Despite increased expression
of integrin α9β1, the expression levels of mRNA and protein
for its ligand EDA were not different between CD133+/CD44+
and CD133-/CD44− cells (Figs. 2e–g).
EDA is required for the sphere formation capacity of
CRC cells
To determine if EDA autocrine and/or paracrine contribute
to the sphere formation capacity of CRC cells, we used a
lentiviral shRNA-based approach to silence EDA expression in
SW480 cells cultured in the serum-free stem cell culture
medium. As shown in Fig. 3, while the tumor cell sphere
formation didn't differ between control shRNA lentivirus-
infected and uninfected SW480 cells, EDA silencing signifi-
cantly reduced the number (Fig. 3a) and the size (Fig. 3b) ofpositively correlated with clinical stages of CRC patients.
pecimens and normal tissues using an anti-EDA antibody. (b) The
= 32 for stages I/II (male = 15, female = 17; b60 years old = 16,
60 years old = 23, ≥60 years old = 22). *, P b 0.01. (c) Statistical
Free Survival of CRC patients (stages I & II, n = 61; stage III, n = 25).
S N 6 included in EDA high). (d) Statistical analysis of the correlation
s (stages I & II, n = 105; stage III, n = 71). P b 0.01 (Kaplan–Meier
gh).
Table 1 The correlation between EDA expression levels and clinicopathological features in colorectal carcinomas.
Variables No. Pts a EDA expression index (IRS) Fisher's (P)
b3 3–7 ≥8
Site 0.03
Colon adenocarcinoma 105 45 (44.8) 33 (31.4) 25 (23.8)
Adjacent colon tissue 10 9 (90.0) 1 (10.0) 0 (0)
Age (years) 0.201
b60 43 15 (34.9) 17 (39.5) 11 (25.6)
≥60 62 32 (51.6) 16 (25.8) 14 (22.6)
Gender 0.668
male 61 27 (44.3) 21 (34.4) 13 (21.3)
female 44 20 (45.5) 12 (27.3) 12 (27.3)
Organ 0.724
Colon 74 32 (43.2) 25 (33.8) 17 (23.0)
rectal 31 15 (48.4) 8 (25.8) 8 (25.8)
Differentiation 0.003
well 31 17 (54.8) 13 (41.9) 1 (3.2)
moderate 48 22 (45.8) 14 (29.2) 12 (25.0)
poor 26 8 (30.8) 6 (23.1) 12 (46.2)
Tumor status 0.435
T2 15 5 (33.3) 6 (40.0) 4 (26.7)
T3 50 27 (54.0) 12 (24.0) 11 (22.0)
T4 40 15 (37.5) 15 (37.5) 10 (25.0)
Nodal status 0.021
N0 75 39 (52.0) 23 (30.7) 13 (17.3)
N1–2 30 8 (26.7) 10 (33.3) 12 (40.0)
Metastasis status 0.048
M0 90 44 (48.9) 28 (31.1) 18 (20.0)
M1 15 3 (20.0) 5 (33.3) 7 (46.7)
Clinical stage 0.000
I + II 61 38 (62.3) 16 (26.2) 7 (11.5)
III + IV 44 9 (20.5) 17 (38.6) 18 (40.9)
a Pts, Patients.
825EDA-integrin α9β1 sustains CD133+/44+ colorectal cancer celltumor cell spheres by ~40% and ~65%, respectively, when
compared to the control shRNA-infected cells.
Since EDA promoted the sphere formation of SW480 cells,
we speculated that EDA silencing may reduce the relative
abundance of CD133 and CD44 positive cell subpopulation in
SW480 cells. Consistently, CD133+ cells were reduced from
90% in the uninfected SW480 cells and 88% in the control shRNA
lentivirus-infected SW480 cells to 56% in the EDA shRNA
lentivirus-infected SW480 cells. Similarly, CD44+ cells fellTable 2 The correlation between EDA expression and clinical ob
Variables No. Pts a EDA expre
b3
Objective response rate
Complete response 20 12 (60.0)
Partial response 20 9 (45.0)
Stable disease 16 3 (18.8)
a Pts, Patients.from 58% and 54% in the two control groups to 10% in the EDA
silencing group (Fig. 3c). In agreement with reduced CD133+/
CD44+ cells, EDA shRNA virus-infected SW480 cells expressed
decreased amounts of many embryonic stem cell markers
including SOX2 (Avilion et al., 2003; Wang et al., 2006),
NANOG (Chambers et al., 2003), and OCT3/4 (Nichols et al.,
1998), and increased amounts of protein markers for differ-
entiated cells such as cytokeratin 7 (CK7) and mucin 2 (MUC2)
(Shin et al., 2010) (Fig. 3d).jective response rate of advanced CRC patients.
ssion index (IRS) Fisher's (P)
3–7 ≥8
0.034
6 (30.0) 2 (10.0)
4 (20.0) 7 (35.0)
4 (25.0) 9 (56.3)
Figure 2 Frequent co-existence of EDA or integrin α9β1 with stem cell markers in CRC tissues and increased expression of integrin
α9β1 in CD133+/CD44+ cancer cells. (a) Immunofluorescence histochemistry of CRC specimens demonstrating OCT3/4 (red)
localization in the region with abundant EDA expression (green), co-localization (purple, marked with white arrows) of OCT3/4 (red)
with nucleus (DAPI blue), and co-localization (yellow, marked with white arrows) of integrin α9β1 (red) with CD133 (green). (b)
Quantification of the positive rates of OCT3/4+, CD133+, integrin α9β1+ and CD133+/integrin α9β1+ cells based on the
immunofluorescence staining. (e–f) The mRNA and protein levels of integrin α9β1 and EDA in CD133/CD44 double positive and
double negative subpopulations of SW480 cells. *, P b 0.01.
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clonogenicity of CD133+/CD44+ cells and for
proliferation of CRC cells
Since EDA has been shown to function through binding to its
receptor integrin α9β1 in SW480 cancer cells (Shinde et al.,
2008), we examined the effect of EDA silencing on the
interaction of EDA and integrin α9β1 in SW480 cells by
immunoprecipitation. As shown in Fig. 4a, EDA silencing
dramatically reduced immunoprecipitable integrin α9β1,
indicating the existence of EDA and integrin α9β1 interac-
tions in these cells.
To determine if EDA requires integrin α9β1 to promote
proliferation of CRC cells, we stably overexpressed EDA in
CD133+/CD44+ cells sorted from SW480 cells in order to
amplify the interaction between EDA and integrin α9β1, and
then treated these CD133+/CD44+ cells with an integrin α9β1
blocking antibody or an isotope control antibody. Inhibition
of integrin α9β1 function in EDA overexpressing CD133+/
CD44+ cells significantly decreased tumor cell sphere
formation (data not shown). Strikingly, integrin α9β1
blocking antibody treatment reduced the number and the
size of CD133+/CD44+ cell colonies by ~94 and 97%,
respectively, when compared to isotype control antibody
treatment, which didn't significantly alter CD133+/CD44+
cell colony formation relative to un-treated group (Fig. 4b).
To show that EDA plays a predominant role in promoting CRC
cell proliferation, CD133+/CD44+cells were infected with
lentiviruses overexpressing EDB, another major alternativelyspliced form of fibronectin. As shown in Fig. 4c, EDA
antibody still substantially inhibited cancer cell colony
formation even EDB was overexpressed. Collectively, our
data suggest that the EDA-integrin α9β1 interaction plays a
critical role for the proliferation of CRC cells.
To determine how integrin α9β1 inhibition influences
SW480 cell proliferation, we performed cell cycle analysis
and found that the G2 + S phase fraction in the integrin
α9β1 antibody-treated SW480 cells fell to ~50% of two
control groups (Fig. 4d), and consistently, the expression of
cyclin D1, a protein known to promote cell cycle progression
through G1–S phase (Fu et al., 2004) was suppressed
(Fig. 4f). We also found that the apoptosis in integrin α9β1
antibody-treated SW480 cells significantly increased (Fig. 4e),
and three apoptotic protein markers, including cleaved
caspase 3, cleaved caspase 9, and cleaved poly (ADP-ribose)
polymerase (PARP), were up-regulated in the integrin α9β1
antibody-treated SW480 cells (Fig. 4f).EDA silencing reduces activation of FAK/ERK/β-
catenin signaling pathway in CD133+/CD44+ colon
cancer cells
TheWnt/β-catenin pathway is critical in the development and
progression of CRCs (Kinzler and Vogelstein, 1996). We
therefore measured beta-catenin protein levels in these cell
subpopulations and in the entire cell population of SW480. As
expected, CD133+/CD44+ versus CD133−/CD44− cells express
Figure 3 EDA silencing reduces sphere formation capacity and CD133+ and CD44+ subpopulations of SW480 cells. (a, b) Images and
quantification of the number and size of spheres formed from SW480 cells without lentiviral infection (uninfected) or infected with
lentiviruses expressing control shRNA or EDA shRNA under serum-free stem cell culture conditions as described in Methods. (c) The
percentage of CD133+ and CD44+ subpopulations determined by flow cytometry in the same cell groups. (d) Western blots of embryonic
stemcell markers (SOX2, NANOG, andOCT3/4) and differentiationmarkers (CK7 andMUC2) in the same cell groups. *, P b 0.05 (vs. control
shRNA).
827EDA-integrin α9β1 sustains CD133+/44+ colorectal cancer cellmore abundant beta-catenin protein and the expression level
of beta-catenin in the entire cell population is in the middle of
two subpopulations (Fig. 5a). To determine if inhibiting EDA
suppresses Wnt/β-catenin pathway, we measured levels of
active β-catenin in EDA shRNA-treated SW480 cells and found
that the active β-catenin was substantially reduced in EDA
shRNA-treated SW480 cells relative to control groups (Fig. 5B).
Since FAK is a downstream mediator of integrin signaling
(Cabodi et al., 2010) and plays an important role in
maintaining the properties of embryonic and cancer stem
cells (Ginestier et al., 2010; Lee et al., 2011), we then
explored whether FAK is involved in the suppression of Wnt
signaling by EDA silencing. Indeed, EDA silencing in SW480
cells dramatically reduced phosphorylation of FAK as well as
the two FAK downstream kinases Akt and Erk1/2 (Cabodi et
al., 2010) (Fig. 5b). We have previously generated a plasmid
expressing FAK shRNA that can efficiently silence FAK in
SW480 cells (Chen et al., 2010). To determine if EDA requires
FAK to activate β-catenin, this FAK shRNA plasmid was
transiently transfected into SW480-derived CD133+/CD44+
cells stably overexpressing EDA. In these EDA-overexpressing
CD133+/CD44+ cells, there was abundant expression of active
β-catenin protein, and FAK shRNA dramatically attenu-
ated the expression of active β-catenin protein in EDA-
overexpressing CD133+/CD44+ cells (Fig. 5c). Since both
PI3K-Akt pathway and MAPK-Erk pathway are downstream
targets of FAK and both phospho-Akt and phospho-Erk were
reduced in EDA shRNA-treated SW480 cells (Fig. 5b), to
determine the relative contribution of PI3K-Akt and
MAPK-Erk in EDA-mediated activation of β-catenin, we
treated EDA-overexpressing CD133+/CD44+ cells with aPI3K-Akt pathway inhibitor LY294002 and a MAPK-Erk pathway
inhibitor PD98059. As shown in Fig. 5e, only the MAPK-Erk
inhibitor PD98059 can reduce expression of activeβ-catenin in
EDA-overexpressing CD133+/CD44+ cells, suggesting a pre-
dominant role of MAPK-Erk pathway in mediating EDA-induced
activation of β-catenin. On the contrary, FAK knockdown,
PI3K/Akt inhibitor or MAPK/Erk inhibitor treatment has no
effect on β-catenin in CD133−/CD44− cells (Figs. 5 d, f). Based
on these observations, we proposed a signaling pathway for
EDA regulation of β-catenin activity in Fig. 5g.
EDA silenced SW480 cells show reduced
tumorigenic capacity
To determine the in vivo significance of our in vitro
observations, we subcutaneously injected both thighs of
each nude mouse (3 mice per group) with equal numbers
(1.0 × 105 per mouse) of control or EDA knockdown SW480
cells. The xenografts in EDA knockdown group generated
significantly slower than control groups (Fig. 6a). Addition-
ally, EDA knockdown SW480 cells showed significantly
reduced tumor diameters (Fig. 6b) and a 60% reduction in
tumor weight (Fig. 6c).
Xenografts derived from EDA-silenced SW480 cells
express reduced proliferation maker and show
increased apoptosis
The volume of a tumor is balanced by proliferation and
apoptosis of tumor cells. To address why EDA-silenced
Figure 4 Blocking EDA and integrin α9β1 function reduces clonogenicity of CD133+/CD44+ cells and promotes apoptosis in SW480
cells. (a) Co-immunoprecipitation assay showing interactions of EDA with integrin a9β1 in SW480 cells. (b) Images and
quantification of the number and size of colonies formed from SW480-derived CD133+/CD44+ cells that were stably infected with
EDA-expressing lentiviruses and then treated without (Untreated) or with isotype control antibody (Ab) (20 ng/ml) or integrin a9β1
blocking antibody (20 ng/ml). *, P b 0.05 (vs. isotype antibody). (c) Images and quantification of the number and size of colonies
formed from SW480-derived CD133+/CD44+ cells that were stably infected with EDB-expressing lentiviruses and then treated
without (Untreated) or with isotype control antibody (Ab) (20 ng/ml) or EDA blocking antibody (IST-9) (20 ng/ml). *, P b 0.05 (vs.
isotype antibody). (d) Cell cycle distributions determined by FACS analysis of whole SW480 cells treated with the antibodies.
(e) Annexin V-7AAD FACS assay of cell apoptosis. P b 0.0001. (f) Western blots of a cell cycle progression-promoting protein cyclin
D1 and apoptosis-related proteins (cleaved caspase 3, caspase 9, and PARP) in whole SW480 cells treated with the antibodies.
828 J. Ou et al.SW480 cells grew slower in xenografts, we did immunohis-
tochemistry using the EDA antibody and an antibody against
a proliferation marker Ki67, and performed TUNEL assays in
xenografts collected from three groups of nude mice
(Fig. 6d). As expected, EDA was almost undetectable in the
xenografts derived from EDA shRNA lentivirus-infected SW480
cells. The expression of Ki67 was substantially lower in
these xenografts relative to those from the two control
groups. TUNEL assays revealed a dramatic increase in
apoptosis in EDA shRNA xenografts. Immunofluorescence
staining showed that the frequency of CD133+/CD44+
cells was reduced in EDA shRNA xenografts. Meanwhile,
there were decreased expression levels of progenitor cell
markers, including OCT3/4, GLUT-1 (Li et al., 2009b),and the activated form of β-catenin in these xenografts
(Fig. 6e).EDA-silenced SW480 cells show reduced metastasis
To determine if EDA expression influences tumormetastasis, we
injected nude mice by tail vein either SW480 cells without
infection of any lentiviruses, or with lentiviruses expressing
either control shRNA or EDA shRNA, and then compared the
incidence of liver and lung metastases 8 weeks after injection.
The gross appearance and H&E staining of tissues showed a
significant decrease in the number and the size of liver
metastases in the mice injected with EDA silenced SW480 cells
Figure 5 FAK/ERK/β-catenin pathway is involved in EDA-integrin α9β1 signal transduction. (a) Western blots of active β-catenin in
CD133+/CD44+, CD133−/CD44− and the whole bulk of SW480 cells. (b) Western blots of active β-catenin as well as phosphorylated and
total FAK, ATK and ERK1/2 in whole SW480 cells without lentiviral infection (Uninfected) or infected with lentiviruses expressing
control shRNA or EDA shRNA. (c) Western blots of active β-catenin in SW480-derived CD133+/CD44+ that were stably infected with
EDA-expressing lentiviruses and then transiently transfected with a control shRNA plasmid or FAK shRNA plasmid. (d) Western blots of
active β-catenin in SW480-derived CD133−/CD44− transiently transfected with a control shRNA plasmid or FAK shRNA plasmid. (e–f)
Western blots of active β-catenin in EDA-overexpressing CD133+/CD44+ cells or in CD133−/CD44− cells treated with a PI3K/AKT inhibitor
LY294002 (25 μmol/ml) and a MAPK/ERK inhibitor PD98059 (25 μmol/ml) for 24 h. (g) Proposed EDA signaling pathway in CRC cells.
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Similar changes were observed for lung metastases (Fig. 6g).Discussion
The major finding of this study was that EDA-integrin α9β1
pathway is required for maintaining CD133 and CD44 positivesubpopulations and tumorigenic capacity of CRC cells. We
provided several pieces of evidence supporting involvement
of FAK/ERK/β-catenin pathway in EDA-α9β1 function. To
our knowledge, this study is the first to link EDA to CD133+/
CD44+ subpopulation properties and Wnt/β-catenin activity
of cancer cells.
It is interesting to find that EDA level in tumor tissues and
patient blood samples is positively correlated to the clinical
Figure 6 EDA silencing reduces tumorigenic and metastatic capacity of SW480 cells. Equal numbers (1.0 × 105 per mouse) of SW480
cells without lentiviral infection or with lentiviruses expressing control shRNA or EDA shRNA were injected subcutaneously into the
both thighs of Balb/c nude mice. (a) The in vivo imaging of xenografts. Note: mice in the uninfected group showed no fluorescence
due to the absence of lentiviral infection and thus normal instead of fluorescent images are included here. A photograph of a
representative xenograft in each group is also shown. (b, c) The maximum diameters and weight of xenografts produced by SW480
cells without lentiviral infection or infected with lentiviruses expressing control shRNA or EDA shRNA. * P, b0.05 (vs. control shRNA).
(d) Immunohistochemistry of expression levels of EDA and a proliferation protein marker Ki67, and TUNEL assays for apoptosis in
xenografts formed 6 weeks after injection of SW480 cells without lentiviral infection or infected with lentiviruses expressing control
shRNA or EDA shRNA. (e) Immunofluorescence staining of CD133, CD44, OCT3/4, GLUT-1 and activated β-catenin in the same tumor
xenografts. (f) Equal numbers (1.0 × 106 per mouse) of SW480 cells without lentiviral infection or with lentiviruses expressing control
shRNA or EDA shRNA were injected via the tail vein into Balb/c nude mice. The gross appearance of livers and lungs 8 weeks post
injection and H&E staining of liver and lung sections.
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831EDA-integrin α9β1 sustains CD133+/44+ colorectal cancer cellstages and chemoresistance of CRC patients (Fig. 1,
Table 1). Advanced stage cancer cells may secrete increased
amounts of EDA into the circulation. Alternatively, stromal
tissues such as tumor-associated fibroblasts and blood/
lymphatic vessels in patients bearing advanced CRCs may
synthesize and secrete more EDA in response to aggressive-
ness of tumors. Increased immunohistochemical staining of
EDA in the tissues of advanced CRCs may reflect either
increased expression of EDA by cancer cells and/or retention
of EDA from other sources as a result of increased expression
of EDA receptors in cancer cells. Although we didn't focus on
how EDA is enriched in advanced human CRCs in this study,
we believe future studies specifically addressing this issue
would be of clinical importance.
CRC, like other cancers, displays remarkable heterogene-
ity. Several subpopulations of CRC cells from human surgical
specimens and cultured cell lines have been identified to
display more significant proliferation and metastatic proper-
ties, including cells positive for CD133 and for CD44 (Dalerba
et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007;
Yeung et al., 2010). Although our study found no differential
expression of EDA between CD133+/CD44+ and CD133−/CD44−
cells sorted from SW480 CRC cells, we did see a significantly
increased expression of an EDA receptor integrin α9β1 in
CD133+/CD44+ cells (Figs. 2b–e), which may cause enrichment
of both autocrine and paracrine EDA in CD133+/CD44+ cells
via ligand-receptor interactions, thereby amplifying EDA
signaling in this subset of cancer cells. This observation has
an important application because it suggests that integrin
α9β1may be a potential cell surfacemarker for enrichment of
CSCs and for prediction of disease progression in CRCs. Indeed,
some integrins have been used for selection of normal neural
stem/progenitor cells (α6 and β1 integrins) (Hall et al., 2006;
Lathia et al., 2010) and cancer progenitor cells from breast
(β3 integrin) (Vaillant et al., 2008) and prostate (α2and β1
integrins) (Patrawala et al., 2007). Future studies are required
to determine if integrin α9β1-enriched CRC cells are true
cancer stem/progenitor cells.
In this study, CD133−/CD44− CRC cells are considered
important in tumor progression because they secrete EDA
and can sustain EDA-integrin α9β1 pathway in a paracrine
manner. CD133+/CD44+ cells may take advantage of CD133−/
CD44− cells-secreted EDA via increasing expression of EDA
receptor integrin α9β1. Interestingly, EDA silencing in SW480
cells changes relative abundance of CD133+/CD44+ and
CD133−/CD44− subpopulations, indicating an EDA-dependent
dynamic equilibrium between these two subsets of cells. A
recent report found that CD133− relative to CD133+ human
CRC cells are more resistant to 5-fluorouracil (FU) (Hongo et
al., 2011). Collectively, these findings highlight the impor-
tance of cancer therapy targeting non-CSCs and tumor
microenvironment in addition to CSCs.
Silencing EDA strikingly reduces the formation of spheroids
in SW480 cells, which is associated with reduced CD133+ and
CD44+ subpopulations and expression of several embryonic
stem cell markers including SOX2, NANOG, and OCT3/4
(Fig. 3). In contrast, the expression of differentiation-related
marker CK7 and MUC2 are increased (Fig. 3). These
observations demonstrated that EDA signaling is required
for sustaining CD133+/CD44+ subpopulation and sphere
formation of SW480 cells, and EDAmay act throughmaintaining
expression levels of stemness-associated proteins. We showedthat EDA interacts with its receptor integrin α9β1 in SW480
cells (Fig. 4a). When integrin α9β1 function is blocked by
an monoclonal antibody, the colony formation of EDA-
overexpressing CD133+/CD44+ cells and the cell cycle
progression of bulk SW480 cells are substantially suppressed,
which is associated with increased apoptosis (Figs. 4b–f).
These findings support a central role of integrin α9β1 in EDA
signaling, at least, in SW480 CRC cells. It is well established
that integrins alone or their interactions with growth factors
and chemokines in a paracrine and autocrine manner pro-
motes the evolution, progression and metastasis of tumors
(Desgrosellier and Cheresh, 2010). Given this, integrins are
considered as potential therapeutic targets in cancer (Cox et
al., 2010).
What might be signal transduction pathways downstream
of EDA-integrin α9β1 signaling? Wnt signaling plays impor-
tant roles in sustaining stem cells in normal tissues and
cancers (Logan and Nusse, 2004) and in the development of
CRC (Kinzler and Vogelstein, 1996; Sancho et al., 2004). We
observed a substantial downregulation of active β-catenin
protein in fibronectin EDA silenced SW480 cells, indicating
suppression of Wnt signaling by EDA silencing in these cells.
To the best of our knowledge, this study is the first to show
that EDA is required for maintaining Wnt/β-catenin activity.
Our observation raised an interesting question of how EDA is
linked to the regulation of β-catenin. We found that the
phosphorylation of FAK, Akt and Erk is down-regulated in the
EDA-silenced SW480 cells (Fig. 5a). FAK is an immediate
downstream target of integrins. Interestingly, silencing of
FAK also reduces activation of β-catenin (Fig. 5b). FAK may
exert effects through Akt and/or Erk pathways (Cabodi
et al., 2010). Additionally, Akt was shown to link FAK to
β-catenin activation in breast cancer progenitor cells
exposed to the interleukin 8 receptor CXCR1, playing a
crucial role in maintaining the properties of these cells
(Ginestier et al., 2010). It was also reported that the Erk
pathway can regulate β-catenin activation (Kim et al.,
2007). Using specific inhibitors of MAPK/Erk and PI3K/Akt
pathways, we showed that activation of β-catenin requires
MAPK/Erk pathway, but not PI3K/Akt pathway in our cells
(Fig. 5c). Thus, we propose that EDA may sustain CD133+/
CD44+ subpopulation in CRC cells via activating Wnt signaling
through integrin α9β1-FAK-MAPK/ERK pathway (Fig. 5g).
More than 20 years ago, Gradl et al. identified fibronectin as
a direct target of Wnt/β-catenin pathway (Gradl et al.,
1999). Together with our finding that fibronectin EDA sustains
β-catenin activity, it appears there is a feed-forward regulatory
loop between fibronectin secretion and β-catenin activity. This
loop may represent a vicious cycle for promoting cell growth.
Thus, targeting this cycle in cancer cells might be effective in
controlling cancer growth.
While the in vivo significance of our in vitro findings
was examined in xenograft and metastasis studies, we
observed a dramatic suppression of tumor growth and
metastasis of SW480 CRC cells by EDA silencing, which is
associated with increased apoptosis and reduced expres-
sion of a cell proliferation marker Ki67, progenitor cell/
embryonic stem cell markers CD133, CD44, OCT3/4 and
GLUT-1, and active form of β-catenin (Fig. 6). This finding
is important because it uncovered a crucial role of EDA in
sustaining tumorigenic and metastatic capacity of CRC
cells in animal models.
832 J. Ou et al.Targeting the extra domain B (EDB) of fibronectin or using
EDB for drug delivery has proved very successful in cancer
treatment (Borsi et al., 2003; Huang et al., 1997; Kaspar et
al., 2006; Santimaria et al., 2003; Sauer et al., 2009). EDA
has not been selected as a target for cancer therapy. Our
observations that EDA is enriched in advanced human CRCs
and that there is an increased expression of an EDA receptor
integrin α9β1 in CD133+/CD44+ subpopulation of CRC cells
support a potential benefit of EDA/integrin α9β1-based
targeting approach for inhibiting cancer progression and for
limiting colon cancer progenitor cells.Abbreviations
CRC colorectal cancer
EDA extra domain A of fibronectin
FAK focal adhesion kinase
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